Clinical Trials Logo

CML, Chronic Phase clinical trials

View clinical trials related to CML, Chronic Phase.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05367700 Recruiting - CML, Chronic Phase Clinical Trials

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

Start date: April 28, 2022
Phase: Phase 1
Study type: Interventional

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.

NCT ID: NCT05353205 Recruiting - CML, Chronic Phase Clinical Trials

A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Start date: November 23, 2021
Phase: Phase 4
Study type: Interventional

It's a double-blind , randomized ,multi-center study. The purpose of this study is to explore the efficacy and safety of flumatinib 400mg once daily (QD) versus 600mg QD as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).

NCT ID: NCT03459534 Recruiting - Clinical trials for Chronic Myeloid Leukemia, Chronic Phase

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Start date: June 25, 2018
Phase: Phase 3
Study type: Interventional

In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173 subjects are expected to be enrolled in a single arm with the administration of Radotinib 400mg twice daily, which includes 10% of dropout rate.

NCT ID: NCT02949570 Recruiting - CML, Chronic Phase Clinical Trials

Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

ICT10
Start date: February 2014
Phase: Phase 2
Study type: Interventional

To assess the efficacy of inecalcitol in combination with imatinib in CML patients with molecular residual disease on imatinib monotherapy.